search
Back to results

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
JTT-851
Glimepiride
Placebo for Active
Placebo for comparator
Sponsored by
Akros Pharma Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females with type 2 diabetes, 18-70 years of age at Visit 1
  • Managing diabetes with diet and exercise only or currently being treated with a stable dose of metformin (at least 1500 mg/day)
  • Glycosylated hemoglobin at Visit 1 between 7.5% and 10.0%, if on metformin and between 7.5% and 10.9%, if without treatment
  • Body mass index (BMI) ≥ 23.0 kg/m^2 and ≤ 45.0 kg/m^2 at Visit 1

Exclusion Criteria:

  • Females who are pregnant or breast-feeding
  • Known medical history or presence of type 1 diabetes or acute metabolic diabetic complications, unstable or rapidly progressing retinopathy, nephropathy or neuropathy
  • Acute coronary syndrome or uncontrolled hypertension
  • Does not meet all diet or previous/concomitant medication restriction criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

JTT-851 Dose 1

JTT-851 Dose 2

JTT-851 Dose 3

Glimepiride Dose 1

Placebo active & Placebo comparator

Arm Description

JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks

JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks

JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks

Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks

Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks

Outcomes

Primary Outcome Measures

Change in glycosylated hemoglobin (HbA1c) after administration of JTT-851
To investigate the change in glycosylated hemoglobin (HbA1c) after JTT-851 administration, once daily for 12 weeks

Secondary Outcome Measures

Safety and tolerability of JTT-851 in patients with type 2 diabetes compared to glimepiride and placebo
To evaluate the safety and tolerability of JTT-851 when administered for 12 weeks in patients with type 2 diabetes compared to glimepiride and placebo.
Effect on ancillary efficacy measures
To investigate the effect of JTT-851 administration on ancillary efficacy measures in patients with type 2 diabetes compared to glimepiride and placebo.
Pharmacokinetics of JTT-851 and its metabolites
To evaluate the pharmacokinetics of JTT-851 and its metabolites in patients with type 2 diabetes

Full Information

First Posted
October 2, 2012
Last Updated
July 25, 2013
Sponsor
Akros Pharma Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01699737
Brief Title
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
Official Title
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Akros Pharma Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.
Detailed Description
This is a randomized, double-blind, double-dummy, placebo and active-controlled (glimepiride), multi-center, parallel-group study to investigate the effect of JTT-851 on HbA1c and other ancillary efficacy parameters and to assess the safety, tolerability, and pharmacokinetics of JTT-851 in inadequately-controlled treatment-naïve or metformin-treated type 2 diabetic patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
325 (Actual)

8. Arms, Groups, and Interventions

Arm Title
JTT-851 Dose 1
Arm Type
Experimental
Arm Description
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
Arm Title
JTT-851 Dose 2
Arm Type
Experimental
Arm Description
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
Arm Title
JTT-851 Dose 3
Arm Type
Experimental
Arm Description
JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
Arm Title
Glimepiride Dose 1
Arm Type
Active Comparator
Arm Description
Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
Arm Title
Placebo active & Placebo comparator
Arm Type
Placebo Comparator
Arm Description
Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
JTT-851
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
Encapsulated Glimepiride tablets
Intervention Type
Drug
Intervention Name(s)
Placebo for Active
Intervention Type
Drug
Intervention Name(s)
Placebo for comparator
Primary Outcome Measure Information:
Title
Change in glycosylated hemoglobin (HbA1c) after administration of JTT-851
Description
To investigate the change in glycosylated hemoglobin (HbA1c) after JTT-851 administration, once daily for 12 weeks
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Safety and tolerability of JTT-851 in patients with type 2 diabetes compared to glimepiride and placebo
Description
To evaluate the safety and tolerability of JTT-851 when administered for 12 weeks in patients with type 2 diabetes compared to glimepiride and placebo.
Time Frame
12 weeks
Title
Effect on ancillary efficacy measures
Description
To investigate the effect of JTT-851 administration on ancillary efficacy measures in patients with type 2 diabetes compared to glimepiride and placebo.
Time Frame
12 weeks
Title
Pharmacokinetics of JTT-851 and its metabolites
Description
To evaluate the pharmacokinetics of JTT-851 and its metabolites in patients with type 2 diabetes
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Relationship between dose and response of JTT-851
Description
To explore the relationship between the JTT-851 dose (exposure) and response
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females with type 2 diabetes, 18-70 years of age at Visit 1 Managing diabetes with diet and exercise only or currently being treated with a stable dose of metformin (at least 1500 mg/day) Glycosylated hemoglobin at Visit 1 between 7.5% and 10.0%, if on metformin and between 7.5% and 10.9%, if without treatment Body mass index (BMI) ≥ 23.0 kg/m^2 and ≤ 45.0 kg/m^2 at Visit 1 Exclusion Criteria: Females who are pregnant or breast-feeding Known medical history or presence of type 1 diabetes or acute metabolic diabetic complications, unstable or rapidly progressing retinopathy, nephropathy or neuropathy Acute coronary syndrome or uncontrolled hypertension Does not meet all diet or previous/concomitant medication restriction criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hisashi Kodama, Ph.D.
Organizational Affiliation
Akros Pharma Inc.
Official's Role
Study Chair
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Dothan
State/Province
Alabama
Country
United States
City
Huntsville
State/Province
Alabama
Country
United States
City
Montgomery
State/Province
Alabama
Country
United States
City
Muscle Shoals
State/Province
Alabama
Country
United States
City
Glendale
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Little Rock
State/Province
Arkansas
Country
United States
City
Artesia
State/Province
California
Country
United States
City
Beverly Hills
State/Province
California
Country
United States
City
Buena Park
State/Province
California
Country
United States
City
Chino
State/Province
California
Country
United States
City
Garden Grove
State/Province
California
Country
United States
City
Lincoln
State/Province
California
Country
United States
City
Lomita
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Newport Beach
State/Province
California
Country
United States
City
North Hollywood
State/Province
California
Country
United States
City
Paramount
State/Province
California
Country
United States
City
Sacramento
State/Province
California
Country
United States
City
Spring Valley
State/Province
California
Country
United States
City
Walnut Creek
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Cooper City
State/Province
Florida
Country
United States
City
Ft. Lauderdale
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Kissimee
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Miramar
State/Province
Florida
Country
United States
City
Ocala
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Ormond Beach
State/Province
Florida
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
Port Orange
State/Province
Florida
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Columbus
State/Province
Georgia
Country
United States
City
Marietta
State/Province
Georgia
Country
United States
City
Nampa
State/Province
Idaho
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Evanston
State/Province
Illinois
Country
United States
City
Indianapolis
State/Province
Indiana
Country
United States
City
Wichita
State/Province
Kansas
Country
United States
City
Lake Charles
State/Province
Louisiana
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Oxon Hill
State/Province
Maryland
Country
United States
City
Olive Branch
State/Province
Mississippi
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Berlin
State/Province
New Jersey
Country
United States
City
Mine Hill
State/Province
New Jersey
Country
United States
City
Glen Falls
State/Province
New York
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Kettering
State/Province
Ohio
Country
United States
City
Marion
State/Province
Ohio
Country
United States
City
Munroe Falls
State/Province
Ohio
Country
United States
City
Wadsworth
State/Province
Ohio
Country
United States
City
Norman
State/Province
Oklahoma
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Eugene
State/Province
Oregon
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Lansdale
State/Province
Pennsylvania
Country
United States
City
Columbia
State/Province
South Carolina
Country
United States
City
Greer
State/Province
South Carolina
Country
United States
City
Carrollton
State/Province
Texas
Country
United States
City
Corpus Christi
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Plano
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Sugarland
State/Province
Texas
Country
United States
City
Tomball
State/Province
Texas
Country
United States
City
Murray
State/Province
Utah
Country
United States
City
Orem
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
Burke
State/Province
Virginia
Country
United States
City
Manassas
State/Province
Virginia
Country
United States
City
Norfolk
State/Province
Virginia
Country
United States
City
Suffolk
State/Province
Virginia
Country
United States
City
Madison
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs